Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 10Completed 9Active not recruiting 7Not yet recruiting 4Unknown 3Terminated 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 5Genitourinary 4Head & Neck 3Endocrine 3Gynecologic 2CNS 2Thoracic 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1Classical hematology 1Breast 1

Conditions

Recurrence 1Ovarian Neoplasms 1Endometrial Neoplasms 1

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × lenvatinib × Gynecologic × Clear all
NCT05263492 2025-10-02

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

Virginia Commonwealth University

Phase 2 Terminated
4 enrolled 8 charts
Gynecologic

Recurrence, Endometrial Neoplasms

NCT01133756 2023-06-22

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Eisai Inc.

Phase 1/2 Terminated
7 enrolled 6 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡